Skip to content

Ginkgo Bioworks to Become a Public Company and Expand its Leading Platform for Cell Programming

Vinson & Elkins Advises Certain Stockholders of Ginkgo Bioworks in Business Combination Agreement with Soaring Eagle Acquisition Corp. Background Image

Vinson & Elkins advised certain stockholders of Ginkgo Bioworks, Inc. (“Ginkgo”), including Viking Global Investors, in connection with a business combination agreement between Ginkgo, which is building the leading horizontal platform for synthetic biology, and Soaring Eagle Acquisition Corp., a publicly traded special purpose acquisition company, that will result in Ginkgo becoming a publicly-listed company.

The transaction values Ginkgo at a $15 billion pre-money equity valuation and is expected to provide up to $2.5 billion of primary proceeds. V&E also advised the stockholders in their PIPE investments in the transaction.

The V&E corporate team was led by partners John Kupiec and Ramey Layne and senior associate Stancell Haigwood. Also advising were counsel Julia Petty; partners Jason McIntosh and David Peck and associate Curt Wimberly; and partner Hill Wellford and senior associate Ryan Will.

About Vinson & Elkins
For more than 100 years, Vinson & Elkins has provided deep experience in handling transactions, investments, projects, and disputes worldwide. The firm is a trusted adviser to clients in the most important industrial and digital industries. Learn more by visiting www.velaw.com or follow us on Twitter @VinsonandElkins or connect with us on LinkedIn.

For more information, please speak with our media contacts.